Investors & Media

Investors & Media

Corporate Profile

At Travere Therapeutics, our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Volume: 52 Week High: 52 Week Low:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Aug 22, 2022
SAN DIEGO and ST. GALLEN , Switzerland , Aug. 22, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) and CSL Vifor today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare kidney disorder and leading cause of end-stage kidney disease (ESKD).